Identification of lipid species linked to the progression of Non-Alcoholic fatty liver disease

Current Drug Targets

Volumn 16, Issue 12, 2015, Pages 1293-1300

  Kawano, Yuki ^a   Nishiumi, Shin ^a   Saito, Masaya ^a   Yano, Yoshihiko ^a   Azuma, Takeshi ^a   Yoshida, Masaru ^a,b  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JAPAN AGENCY FOR MEDICAL RESEARCH AND DEVELOPMENT   (Japan)

Author keywords

Hepatic fibrosis; Hepatic inflammation; Insulin resistance; Lipid synthesis; Lipid trafficking; Toxic lipid

Indexed keywords

CHOLINEPHOSPHOTRANSFERASE; FATTY ACID SYNTHASE; GLYCEROLIPID; GLYCEROPHOSPHOLIPID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; INTERLEUKIN 6; MALONALDEHYDE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PERILIPIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHATIDYLSERINE SYNTHASE; SPHINGOLIPID; STEROL REGULATORY ELEMENT BINDING PROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; FATTY ACID; GLYCOLIPID; LIPID; STEROL;

ARTICLE; DISEASE COURSE; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LIVER FIBROSIS; MITOCHONDRIAL RESPIRATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; LIVER; METABOLISM; PHYSIOLOGY;

DISEASE PROGRESSION; FATTY ACIDS; GLYCEROPHOSPHOLIPIDS; GLYCOLIPIDS; HUMANS; LIPID METABOLISM; LIPIDS; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; STEROLS; TRIGLYCERIDES;

EID: 84946750749     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450116666150408103318     Document Type: Article

References (78)

1. [1] Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011; 332(6037): 1519-23.
2. [2] Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol 2013; 48(4): 434-41.
3. [3] Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008; 28(4): 339-50.
4. [4] Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140(1): 124-31.
5. [5] Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 2009; 104(4): 861-7.
6. [6] Targher G, Bertolini L, Poli F, et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005; 54(12): 3541-6.
7. [7] Targher G, Chonchol M, Zoppini G, Abaterusso C, Bonora E. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link? J Hepatol 2011; 54(5): 1020-9.
8. [8] Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114(4): 842-5.
9. [9] Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114(2): 147-52.
10. [10] Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52(5): 1836-46.
11. [11] Fahy E, Cotter D, Sud M, Subramaniam S. Lipid classification, structures and tools. Biochim Biophys Acta 2011; 1811(11): 637-47.
12. [12] Jensen-Urstad AP, Semenkovich CF. Fatty acid synthase and liver triglyceride metabolism: housekeeper or messenger? Biochim Biophys Acta 2012; 1821(5): 747-53.
13. [13] Guillou H, Zadravec D, Martin PG, Jacobsson A. The key roles of elongases and desaturases in mammalian fatty acid metabolism: Insights from transgenic mice. Prog Lipid Res 2010; 49(2): 186-99.
14. [14] Puri P, Baillie RA, Wiest MM, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007; 46(4): 1081-90.
15. [15] Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010; 52(2): 774-88.
16. [16] Han MS, Park SY, Shinzawa K, et al. Lysophosphatidylcholine as a death effector in the lipoapoptosis of hepatocytes. J Lipid Res 2008; 49(1): 84-97.
17. [17] Lopez-Vicario C, Gonzalez-Periz A, Rius B, et al. Molecular interplay between Delta5/Delta6 desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis. Gut 2014; 63(2): 344-55.
18. [18] Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology 2014; 147(2): 377-84.e1.
19. [19] Scorletti E, Bhatia L, McCormick KG, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in non-alcoholic fatty liver disease: Results from the *WELCOME study. Hepatology 2014 ; 60(4): 1211-1221.
20. [20] Ishii H, Horie Y, Ohshima S, et al. Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocytespecific Pten-deficient mice. J Hepatol 2009; 50(3): 562-571.
21. [21] Jenkins CM, Yang J, Sims HF, Gross RW. Reversible high affinity inhibition of phosphofructokinase-1 by acyl-CoA: a mechanism integrating glycolytic flux with lipid metabolism. J Biol Chem 2011; 286(14): 11937-50.
22. [22] Taylor EB, Ellingson WJ, Lamb JD, Chesser DG, Winder WW. Long-chain acyl-CoA esters inhibit phosphorylation of AMPactivated protein kinase at threonine-172 by LKB1/STRAD/MO25. Am J Physiol Endocrinol Metab 2005; 288(6): E1055-61.
23. [23] Neschen S, Morino K, Hammond LE, et al. Prevention of hepatic steatosis and hepatic insulin resistance in mitochondrial acyl-CoA: glycerol-sn-3-phosphate acyltransferase 1 knockout mice. Cell Metab 2005; 2(1): 55-65.
24. [24] Li LO, Ellis JM, Paich HA, et al. Liver-specific loss of long chain acyl-CoA synthetase-1 decreases triacylglycerol synthesis and betaoxidation and alters phospholipid fatty acid composition. J Biol Chem 2009; 284(41): 27816-26.
25. [25] Takeuchi K, Reue K. Biochemistry, physiology, and genetics of GPAT, AGPAT, and lipin enzymes in triglyceride synthesis. Am J Physiol Endocrinol Metab 2009; 296(6): E1195-209.
26. [26] Lagace TA, Ridgway ND. The role of phospholipids in the biological activity and structure of the endoplasmic reticulum. Biochim Biophys Acta 2013; 1833(11): 2499-510.
27. [27] Fagone P, Jackowski S. Phosphatidylcholine and the CDP-choline cycle. Biochim Biophys Acta 2013; 1831(3): 523-32.
28. [28] Hishikawa D, Hashidate T, Shimizu T, Shindou H. Diversity and function of membrane glycerophospholipids generated by the remodeling pathway in mammalian cells. J Lipid Res 2014; 55(5): 799-807.
29. [29] Zhang C, Wendel AA, Keogh MR, Harris TE, Chen J, Coleman RA. Glycerolipid signals alter mTOR complex 2 (mTORC2) to diminish insulin signaling. Proc Natl Acad Sci USA 2012; 109(5): 1667-72.
30. [30] Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster DA. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol Cell Biol 2009; 29(6): 1411-20.
31. [31] Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 2001; 294(5548): 1942-5.
32. [32] Kakisaka K, Cazanave SC, Fingas CD, et al. Mechanisms of lysophosphatidylcholine- induced hepatocyte lipoapoptosis. Am J Physiol Gastrointest Liver Physiol 2012; 302(1): G77-84.
33. [33] Pathil A, Mueller J, Warth A, Chamulitrat W, Stremmel W. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease. Hepatology 2012; 55(5): 1369-78.
34. [34] Stremmel W, Staffer S, Wannhoff A, Pathil A, Chamulitrat W. Plasma membrane phospholipase A2 controls hepatocellular fatty acid uptake and is responsive to pharmacological modulation: implications for nonalcoholic steatohepatitis. FASEB J 2014; 28(7): 3159-70.
35. [35] Li Z, Agellon LB, Allen TM, et al. The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab 2006; 3(5): 321-31.
36. [36] Fu S, Yang L, Li P, et al. Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity. Nature 2011; 473(7348): 528-31.
37. [37] Jacobs RL, Zhao Y, Koonen DP, et al. Impaired de novo choline synthesis explains why phosphatidylethanolamine Nmethyltransferase- deficient mice are protected from diet-induced obesity. J Biol Chem 2010; 285(29): 22403-13.
38. [38] Fujita K, Nozaki Y, Wada K, et al. Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology 2009; 50(3): 772-80.
39. [39] Song J, da Costa KA, Fischer LM, et al. Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD). FASEB J 2005; 19(10): 1266-71.
40. [40] Romeo S, Cohen JC, Hobbs HH. No association between polymorphism in PEMT (V175M) and hepatic triglyceride content in the Dallas Heart Study. FASEB J 2006; 20(12): 2180; author reply 1-2.
41. [41] Harris TE, Finck BN. Dual function lipin proteins and glycerolipid metabolism. Trends Endocrinol Metab 2011; 22(6): 226-33.
42. [42] Bickel PE, Tansey JT, Welte MA. PAT proteins, an ancient family of lipid droplet proteins that regulate cellular lipid stores. Biochim Biophys Acta 2009; 1791(6): 419-40.
43. [43] Quiroga AD, Lehner R. Liver triacylglycerol lipases. Biochim Biophys Acta 2012; 1821(5): 762-9.
44. [44] Pawella LM, Hashani M, Eiteneuer E, et al. Perilipin discerns chronic from acute hepatocellular steatosis. J Hepatol 2014; 60(3): 633-42.
45. [45] Langhi C, Marquart TJ, Allen RM, Baldan A. Perilipin-5 is regulated by statins and controls triglyceride contents in the hepatocyte. J Hepatol 2014; 61(2): 358-65.
46. [46] Wang C, Zhao Y, Gao X, et al. Perilipin 5 improves hepatic lipotoxicity by inhibiting lipolysis. Hepatology 2015; 61(3): 870-82
47. [47] Yamaguchi K, Yang L, McCall S, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007; 45(6): 1366-74.
48. [48] Birkenfeld AL, Shulman GI. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology 2014; 59(2): 713-23.
49. [49] Jornayvaz FR, Birkenfeld AL, Jurczak MJ, et al. Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2. Proc Natl Acad Sci USA 2011; 108(14): 5748-52.
50. [50] Samuel VT, Liu ZX, Wang A, et al. Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest 2007; 117(3): 739-45.
51. [51] Kotronen A, Seppanen-Laakso T, Westerbacka J, et al. Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Diabetes 2009; 58(1): 203-8.
52. [52] Kumashiro N, Erion DM, Zhang D, et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci USA 2011; 108(39): 16381-5.
53. [53] Magkos F, Su X, Bradley D, et al. Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects. Gastroenterology 2012; 142(7): 1444-6.e2.
54. [54] Pruett ST, Bushnev A, Hagedorn K, et al. Biodiversity of sphingoid bases ("sphingosines") and related amino alcohols. J Lipid Res 2008; 49(8): 1621-39.
55. [55] Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008; 9(2): 139-50.
56. [56] Futerman AH, Riezman H. The ins and outs of sphingolipid synthesis. Trends Cell Biol. 2005; 15(6): 312-8.
57. [57] Pagadala M, Kasumov T, McCullough AJ, Zein NN, Kirwan JP. Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol Metab 2012; 23(8): 365-71.
58. [58] Satapati S, Sunny NE, Kucejova B, et al. Elevated TCA cycle function in the pathology of diet-induced hepatic insulin resistance and fatty liver. J Lipid Res 2012; 53(6): 1080-92.
59. [59] Yang G, Badeanlou L, Bielawski J, Roberts AJ, Hannun YA, Samad F. Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome. Am J Physiol Endocrinol Metab 2009; 297(1): E211-24.
60. [60] Holland WL, Brozinick JT, Wang LP, et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesityinduced insulin resistance. Cell Metab 2007; 5(3): 167-79.
61. [61] Fucho R, Martinez L, Baulies A, et al. ASMase regulates autophagy and lysosomal membrane permeabilization and its inhibition prevents early stage non-alcoholic steatohepatitis. J Hepatol 2014; 61(5): 1126-34.
62. [62] Bijl N, Sokolovic M, Vrins C, et al. Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice. Hepatology 2009; 50(5): 1431-41.
63. [63] Li C, Kong Y, Wang H, et al. Homing of bone marrow mesenchymal stem cells mediated by sphingosine 1-phosphate contributes to liver fibrosis. J Hepatol 2009; 50(6): 1174-83.
64. [64] Moles A, Tarrats N, Morales A, et al. Acidic sphingomyelinase controls hepatic stellate cell activation and in vivo liver fibrogenesis. Am J Pathol 2010; 177(3): 1214-24.
65. [65] Nes WD. Biosynthesis of cholesterol and other sterols. Chem Rev 2011; 111(10): 6423-51.
66. [66] Ikonen E. Cellular cholesterol trafficking and compartmentalization. Nat Rev Mol Cell Biol. 2008; 9(2): 125-38.
67. [67] Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell 2006; 124(1): 35-46.
68. [68] Caballero F, Fernandez A, Lacy AMD, Fernandez-Checa JC, Caballeria J, Garcia-Ruiz C. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J Hepatol 2009; 50(4): 789-96.
69. [69] Teratani T, Tomita K, Suzuki T, et al. A high-cholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in hepatic stellate cells. Gastroenterology 2012; 142(1): 152- 64.e10.
70. [70] Rooyen DMV, Larter CZ, Haigh WG, et al. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology 2011; 141(4): 1393-403, 403.e1-5.
71. [71] Ioannou GN, Morrow OB, Connole ML, Lee SP. Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the United States population. Hepatology 2009; 50(1): 175-84.
72. [72] Tomita K, Teratani T, Suzuki T, et al. Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice. Hepatology 2014; 59(1): 154-69.
73. [73] Simonen P, Kotronen A, Hallikainen M, et al. Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. J Hepatol 2011; 54(1): 153-9.
74. [74] Min HK, Kapoor A, Fuchs M, et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab 2012; 15(5): 665-74.
75. [75] Rooyen DMV, Gan LT, Yeh MM, et al. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. J Hepatol 2013; 59(1): 144-52.
76. [76] Prinz WA. Lipid trafficking sans vesicles: where, why, how? Cell 2010; 143(6): 870-4.
77. [77] Perry RJ, Samuel VT, Petersen KF, Shulman GI. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 2014; 510(7503): 84-91.
78. [78] Leroux A, Ferrere G, Godie V, et al. Toxic lipids stored by Kupffer cells correlates with their pro-inflammatory phenotype at an early stage of steatohepatitis. J Hepatol 2012; 57(1): 141-9.